Intro

The October 2025 digital pathology roundup with Imogen Fitt of Signify Research is here. Recent activity in digital pathology and AI spans new partnerships, implementations, and product launches. Partnerships: Alpenglow Biosciences & VirDx: Collaborating to create large-scale 3D light-sheet microscopy datasets as ground truth for VirDx’s MRI-based prostate cancer diagnostics, using NVIDIA accelerated computing to tightly link radiology and pathology. Aiforia & Siemens Healthineers (Finland): After a broader European deal, Aiforia signed a local co-marketing/sales agreement with Siemens Healthineers’ Finnish affiliate to drive AI adoption in Finnish pathology as part of precision diagnostics. Implementations: Institut Curie: Entered a one-year agreement, funded by ARS Île-de-France, to use Aiforia’s CE-IVD clinical AI tools in routine pathology to support faster, more consistent diagnoses. One Dorset Pathology (NHS): Signed a 7-year managed equipment service to deploy FUJIFILM SYNAPSE® Pathology on AWS, integrating partners like Sysmex, Menarini, Ibex, Barco, and Augnito. The goal is 100% digital reporting and meeting the UK 10-day histology target by early 2026. Moffitt Cancer Center: Will implement four Pramana high-throughput scanners to support clinical and research work, including cytology and blood smears, with phased adoption through 2027. Ouest Pathologie & Dedalus: Planning the largest French roll-out of the integrated Diamic-DeepUnity LIS + imaging platform across Bretagne/Normandie via a 7-year plan starting December 2025, enabling AI, tele-expertise, and unified image management. Product launches & integrations: Aignostics Atlas H&E-TME: Now generally available, offering rapid, single-cell-level TME readouts and >5,000 metrics per image from routine H&E, initially targeting biopharma research. Proscia & Primaa: Integrated a skin AI module into Proscia’s platform for mitoses, hotspots, perineural invasion, and margin metrics in dermatopathology. PathPresenter: Its vendor-agnostic clinical viewer achieved CE-IVDR marking for primary diagnosis in Europe, complementing its FDA 510(k) and enabling broader EU clinical deployments.